{"schema_version":"secwatch.filing_event.v1","accession":"0000037785-26-000083","form_type":"8-K","ticker":"FMC","cik":"0000037785","company_name":"FMC CORP","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.586614+00:00","generated_at":"2026-05-15T02:30:43.611973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FMC Q1 net loss $281M, Adj EBITDA $72M above guidance; reaffirms FY outlook","bullets":["Revenue $759M (-4% YoY); GAAP EPS $(2.25); adj EPS $(0.23); adj EBITDA $72M (-40%).","Board-authorized strategic alternatives evaluation (since Feb 2026) progressing; no transaction assured.","FY 2026 guidance reaffirmed: rev $3.6-3.8B, adj EBITDA $670-730M, adj EPS $1.63-1.89, FCF -$65M to $65M.","Q2 2026 view: rev $850-900M, adj EBITDA $130-150M, adj EPS $0.16-0.26.","New active ingredient sales doubled YoY; Plant Health grew 6%."],"urls":{"canonical":"https://secwatch.observer/filing/0000037785-26-000083","json":"https://secwatch.observer/filing/0000037785-26-000083.json","markdown":"https://secwatch.observer/filing/0000037785-26-000083.md","text":"https://secwatch.observer/filing/0000037785-26-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/37785/000003778526000083/0000037785-26-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/37785/000003778526000083/fmc-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:30:43.611973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41b3a248b2894c33a875d36341db298c44f39fce","claim":"FMC CORP reported full-year 2026 results: revenue $3.60 billion to $3.80 billion, EPS $1.63 to $1.89. Guidance reaffirmed.","evidence_excerpt":"diluted share, down $2.13 versus Q1 2025 • Adjusted loss per diluted share of $0.23, down 41 cents versus Q1 2025 Maintains 2026 Full-Year Outlook 1 • Revenue excluding India of $3.60 billion to $3.80 billion, a decline of 5 percent at the midpoint versus 2025 ◦ Excluding 2025 India contributions the 2026 outlook represents a decline at the midpoint of 3 percent •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/37785/000003778526000083/0000037785-26-000083-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2026"},{"label":"Revenue","value":"$3.60 billion to $3.80 billion"},{"label":"EPS","value":"$1.63 to $1.89"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}